Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists (Q38312460)

2 September 2017

title

Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists (English)

1 reference

2 September 2017

David V Erbe

1

1 reference

2 September 2017

Katherine Gartrell

2

1 reference

2 September 2017

Yan-Ling Zhang

3

1 reference

2 September 2017

Vipin Suri

4

1 reference

2 September 2017

Steven J Kirincich

5

1 reference

2 September 2017

Sarah Will

6

1 reference

2 September 2017

Mylene Perreault

7

1 reference

2 September 2017

Suyue Wang

8

1 reference

2 September 2017

James F Tobin

9

1 reference

2 September 2017

publication date

16 May 2006

1 reference

2 September 2017

published in

Vascular Pharmacology

1 reference

2 September 2017

volume

45

1 reference

2 September 2017

issue

3

1 reference

2 September 2017

page(s)

154-162

1 reference

Peroxisome proliferator-activated receptor gamma regulates angiotensin II-stimulated phosphatidylinositol 3-kinase and mitogen-activated protein kinase in blood vessels in vivo

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

7 January 2021

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

Ertiprotafib improves glycemic control and lowers lipids via multiple mechanisms

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

Fast Calculation of Molecular Polar Surface Area as a Sum of Fragment-Based Contributions and Its Application to the Prediction of Drug Transport Properties

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

Insulin resistance in essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

Obesity wars: molecular progress confronts an expanding epidemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

An angiotensin II AT1 receptor antagonist, telmisartan augments glucose uptake and GLUT4 protein expression in 3T3-L1 adipocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

The impact of ACE inhibitors or angiotensin II type 1 receptor blockers on the development of new-onset type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

Prevention of type 2 diabetes mellitus through inhibition of the Renin-Angiotensin system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

Molecular characterization of new selective peroxisome proliferator-activated receptor gamma modulators with angiotensin receptor blocking activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

Type 2 diabetes: principles of pathogenesis and therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

Cross-talk between the insulin and angiotensin signaling systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

The PROactive study: some answers, many questions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

Drugs targeting the renin-angiotensin-aldosterone system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VPH.2006.05.002

10.1016/J.VPH.2006.05.002

7 January 2021

Identifiers

DOI

1 reference

2 September 2017

1 reference